Captrust Financial Advisors Catalyst Pharmaceuticals, Inc. Transaction History

Captrust Financial Advisors

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 23, 2022	SELL	$6.23 - $8.57 $990 - $1,362	-159 Reduced 20.98%	599 $4,000
Q2 2022 Aug 16, 2022	BUY	$6.23 - $8.57 $2,884 - $3,967	463 Added 156.95%	758 $5,000
Q1 2022 May 16, 2022	SELL	$5.31 - $8.31 $6,212 - $9,722	-1,170 Reduced 79.86%	295 $2,000
Q4 2021 Feb 14, 2022	SELL	$5.21 - $7.45 $3,391 - $4,849	-651 Reduced 30.77%	1,465 $10,000
Q3 2021 Nov 16, 2021	SELL	$4.85 - $6.04 $548 - $682	-113 Reduced 5.07%	2,116 $11,000
Q2 2021 Aug 16, 2021	BUY	$4.29 - $6.05 $484 - $683	113 Added 5.34%	2,229 $13,000
Q1 2021 May 17, 2021	BUY	$3.45 - $4.69 $6,862 - $9,328	1,989 Added 1566.14%	2,116 $10,000
Q3 2020 Nov 17, 2020	BUY	$2.97 - $5.08 $377 - $645	127 New	127 $0

326

94.6M

19.1K

51.1K

Ticker CPRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 102,820,000
Market Cap $2.12B
Description
Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthe...

Get notified when there are updates to the investment portfolio of Captrust Financial Advisors, based on Form 13F filings with the SEC.

Stay updated on Captrust Financial Advisors with notifications on news.